Stock Scorecard
Stock Summary for Lineage Cell Therapeutics Inc (LCTX) - $0.87 as of 9/6/2024 3:55:48 PM EST
Total Score
10 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LCTX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LCTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LCTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LCTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Financial Details for LCTX
Company Overview |
|
|---|---|
| Ticker | LCTX |
| Company Name | Lineage Cell Therapeutics Inc |
| Country | USA |
| Description | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 6/30/2024 |
| Next Earnings Date | 11/7/2024 |
Stock Price History |
|
| Last Day Price | 0.87 |
| Last Day Price Updated | 9/6/2024 3:55:48 PM EST |
| Last Day Volume | 375,879 |
| Average Daily Volume | 517,208 |
| 52-Week High | 1.61 |
| 52-Week Low | 0.77 |
| Last Price to 52 Week Low | 12.99% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 309.61 |
| Sector PE | 80.12 |
| 5-Year Average PE | -10.49 |
| Free Cash Flow Ratio | 4.35 |
| Industry Free Cash Flow Ratio | 17.61 |
| Sector Free Cash Flow Ratio | 30.42 |
| Current Ratio Most Recent Quarter | 2.64 |
| Total Cash Per Share | 0.20 |
| Book Value Per Share Most Recent Quarter | 0.36 |
| Price to Book Ratio | 2.49 |
| Industry Price to Book Ratio | 10.39 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 27.46 |
| Industry Price to Sales Ratio Twelve Trailing Months | 26.85 |
| Sector Price to Sales Ratio Twelve Trailing Months | 6.66 |
Share Statistics |
|
| Total Shares Outstanding | 188,837,000 |
| Market Capitalization | 164,288,190 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.71% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 18.22% |
| Reported EPS 12 Trailing Months | -0.13 |
| Reported EPS Past Year | -0.07 |
| Reported EPS Prior Year | -0.13 |
| Net Income Twelve Trailing Months | -24,187,000 |
| Net Income Past Year | -21,486,000 |
| Net Income Prior Year | -26,273,000 |
| Quarterly Revenue Growth YOY | -56.30% |
| 5-Year Revenue Growth | 12.39% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 38,496,000 |
| Total Cash Past Year | 35,492,000 |
| Total Cash Prior Year | 57,875,000 |
| Net Cash Position Most Recent Quarter | 38,496,000 |
| Net Cash Position Past Year | 34,969,000 |
| Long Term Debt Past Year | 523,000 |
| Long Term Debt Prior Year | 523,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.99 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 63,419,000 |
| Total Stockholder Equity Prior Year | 73,339,000 |
| Total Stockholder Equity Most Recent Quarter | 68,300,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -22,333,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.12 |
| Free Cash Flow Past Year | -29,240,000 |
| Free Cash Flow Prior Year | 646,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.02 |
| MACD Signal | -0.02 |
| 20-Day Bollinger Lower Band | 0.81 |
| 20-Day Bollinger Middle Band | 0.98 |
| 20-Day Bollinger Upper Band | 1.15 |
| Beta | 1.26 |
| RSI | 45.79 |
| 50-Day SMA | 1.08 |
| 150-Day SMA | 1.36 |
| 200-Day SMA | 1.61 |
System |
|
| Modified | 9/7/2024 5:51:15 AM EST |